Raymond James Financial Inc. Makes New Investment in Humana Inc. (NYSE:HUM)

Raymond James Financial Inc. bought a new position in shares of Humana Inc. (NYSE:HUM) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 105,313 shares of the insurance provider’s stock, valued at approximately $26,720,000. Raymond James Financial Inc. owned about 0.09% of Humana at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Proficio Capital Partners LLC bought a new stake in Humana during the 4th quarter worth approximately $14,097,000. Victory Capital Management Inc. grew its holdings in Humana by 73.5% during the 4th quarter. Victory Capital Management Inc. now owns 184,937 shares of the insurance provider’s stock worth $46,920,000 after acquiring an additional 78,351 shares during the last quarter. Commerzbank Aktiengesellschaft FI grew its holdings in Humana by 19.0% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 6,074 shares of the insurance provider’s stock worth $1,541,000 after acquiring an additional 969 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Humana by 7.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider’s stock worth $244,811,000 after acquiring an additional 65,735 shares during the last quarter. Finally, Schechter Investment Advisors LLC bought a new stake in Humana during the 4th quarter worth approximately $244,000. 92.38% of the stock is owned by institutional investors.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.32% of the company’s stock.

Humana Stock Performance

HUM opened at $253.11 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The company’s fifty day moving average price is $271.37 and its two-hundred day moving average price is $280.52. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a market cap of $30.55 billion, a price-to-earnings ratio of 25.44, a PEG ratio of 2.05 and a beta of 0.57.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.40%. Humana’s payout ratio is 35.58%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on HUM shares. Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Morgan Stanley dropped their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Barclays boosted their price target on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Piper Sandler boosted their price target on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Finally, Truist Financial boosted their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.